Literature DB >> 7839446

The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors.

M E Wachs1, W J Amend, N L Ascher, P N Bretan, J Emond, J R Lake, J S Melzer, J P Roberts, S J Tomlanovich, F Vincenti.   

Abstract

Liver allografts from HBcAb(+), IgM(-), HBsAg(-) donors can transmit HBV to uninfected recipients. We currently no longer accept these livers for transplantation while continuing to accept the kidneys. The purpose of this study is to determine the risk of donor-transmitted HBV infections from HBcAb(+), HBIgM(-), HBsAg(-) organ donors and determine if the risk of donor-transmitted HBV infections and their severity is dependent on the organ being transplanted. This study consists of a retrospective review of the posttransplant course of recipients of HBcAb(+), HBIgM(-), HBsAg(-) donors accepted at UCSF from 6/85 to 12/93. Transmitted HBV infection was defined as one in which the recipient changed from HBsAg(-) prior to transplantation to HBsAg(+) posttransplant, with no other source. There were 25 of 1190 donors who were HBcAb(+), HBIgM(-), HBsAg(-); 1/42 kidney, 3/6 liver, and 0/7 heart HBsAg(-) transplant recipients of organs from these donors became HBsAg(+) after transplantation. This difference in infection rate (liver vs. kidney and heart) is statistically significant. The clinical course of the liver recipients was also more severe. All of the patients who became infected were HBsAb(-) and HBcAb(-) prior to transplant. We conclude that (1) HBV can be transmitted from HBcAb(+), HBIgM(-), HBsAg(-) organ donors, (2) the rate of transmission is highest and severity of infection is worst in the liver recipients; and (3) we will continue to transplant kidneys from these donors, preferably into immunized recipients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7839446

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  49 in total

1.  Positive suggestions about the anti-HBc positive donor.

Authors:  D Mutimer
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

2.  Cardiac Transplantation: Pre-transplant Infectious Diseases Evaluation and Post-transplant Prophylaxis.

Authors:  Susan Keay
Journal:  Curr Infect Dis Rep       Date:  2002-08       Impact factor: 3.725

3.  Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts.

Authors:  Masatoshi Ishigami; Hideya Kamei; Taro Nakamura; Yoshiaki Katano; Hisami Ando; Tetsuya Kiuchi; Hidemi Goto
Journal:  J Gastroenterol       Date:  2010-09-11       Impact factor: 7.527

4.  Donor race does not predict graft failure after liver transplantation.

Authors:  Sumeet K Asrani; Young-Suk Lim; Terry M Therneau; Rachel A Pedersen; Julie Heimbach; W Ray Kim
Journal:  Gastroenterology       Date:  2010-02-19       Impact factor: 22.682

5.  Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients?

Authors:  Mehmet Kanbay; Gurden Gur; Ali Akcay; Haldun Selcuk; Ugur Yilmaz; Hande Arslan; Sedat Boyacioglu; Fatma Nurhan Ozdemir
Journal:  Dig Dis Sci       Date:  2006-09-15       Impact factor: 3.199

Review 6.  Hepatitis B virus infection in liver transplant candidates and recipients.

Authors:  Patrick Yachimski; Raymond T Chung
Journal:  MedGenMed       Date:  2005-04-18

7.  Prevention of de novo HBV infection by the presence of anti-HBs in transplanted patients receiving core antibody-positive livers.

Authors:  Rafael Barcena; Gloria Moraleda; Javier Moreno; M Dolores Martín; Emilio de Vicente; Jesús Nuño; M Luisa Mateos; Santos del Campo
Journal:  World J Gastroenterol       Date:  2006-04-07       Impact factor: 5.742

8.  Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers.

Authors:  Watcharasak Chotiyaputta; Shawn J Pelletier; Robert J Fontana; Anna S F Lok
Journal:  Hepatol Int       Date:  2010-07-29       Impact factor: 6.047

Review 9.  Chronic viral hepatitis in kidney transplantation.

Authors:  Janna Huskey; Alexander C Wiseman
Journal:  Nat Rev Nephrol       Date:  2011-02-01       Impact factor: 28.314

Review 10.  Hepatitis B Virus Reactivation in the Setting of Cancer Chemotherapy and Other Immunosuppressive Drug Therapy.

Authors:  Stevan A Gonzalez; Robert P Perrillo
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.